Loading…
Clinicopathological features of cytokeratin 5‐positive pulmonary adenocarcinoma
Cytokeratin 5 (CK5) is a marker for pulmonary squamous cell carcinoma; however, CK5 is sometimes present in pulmonary adenocarcinoma (ADC), and there is insufficient information regarding the clinicopathological features of CK5‐positive ADC. We aimed to explore the clinicopathological characteristic...
Saved in:
| Published in: | Histopathology 2023-02, Vol.82 (3), p.439-453 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3537-993bc980efd70b2a51f3d44c7ee7420fdb855ed1e27cda0acb61ab1eba6324b53 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3537-993bc980efd70b2a51f3d44c7ee7420fdb855ed1e27cda0acb61ab1eba6324b53 |
| container_end_page | 453 |
| container_issue | 3 |
| container_start_page | 439 |
| container_title | Histopathology |
| container_volume | 82 |
| creator | Terada, K Yoshizawa, A Sumiyoshi, S Rokutan‐Kurata, M Nakajima, N Hamaji, M Sonobe, M Menju, T Date, H Haga, H |
| description | Cytokeratin 5 (CK5) is a marker for pulmonary squamous cell carcinoma; however, CK5 is sometimes present in pulmonary adenocarcinoma (ADC), and there is insufficient information regarding the clinicopathological features of CK5‐positive ADC. We aimed to explore the clinicopathological characteristics of CK5‐positive ADC using immunohistochemistry. We prepared the following two cohorts: a resected cohort containing 220 resected tumours for primarily studying the detailed morphological characteristics, and a tissue microarray (TMA) cohort containing 337 samples for investigating the associations of CK5 expression with other protein expressions, genetic and prognostic findings. CK5‐positive ADC was defined to have ≥ 10% tumour cells and presence of CK5‐positive tumour cells in the resected and TMA cohorts, respectively. CK5‐positive ADCs were identified in 91 (16.3%) patients in the combined cohort. CK5‐positive ADCs had male predominance (P = 0.012), smoking history (P = 0.001), higher stage (P |
| doi_str_mv | 10.1111/his.14827 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2725202850</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2725202850</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3537-993bc980efd70b2a51f3d44c7ee7420fdb855ed1e27cda0acb61ab1eba6324b53</originalsourceid><addsrcrecordid>eNp10E9LwzAcxvEgipvTg29ACl700C1_mmY9ylA3GIio55Kmv7rMtqlJq-zmS_A1-kqMdnoQzCWXDw_JF6FjgsfEn8lKuzGJplTsoCFhMQ8p58kuGmKGkxCTWAzQgXNrjIlglO6jAYspS3hMhuh2VupaK9PIdmVK86iVLIMCZNtZcIEpArVpzRNY2eo64B9v741xutUvEDRdWZla2k0gc6iNklbp2lTyEO0VsnRwtL1H6OHq8n42D5c314vZxTJUjDMRJgnLVDLFUOQCZ1RyUrA8ipQAEBHFRZ5NOYecABUql1iqLCYyI5DJmNEo42yEzvrdxprnDlybVtopKEtZg-lcSgXlFNMpx56e_qFr09nav86rOPbGt_DqvFfKGucsFGljdeU_mBKcfnVOfef0u7O3J9vFLqsg_5U_YT2Y9OBVl7D5fymdL-76yU8fbYlK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2766285561</pqid></control><display><type>article</type><title>Clinicopathological features of cytokeratin 5‐positive pulmonary adenocarcinoma</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Terada, K ; Yoshizawa, A ; Sumiyoshi, S ; Rokutan‐Kurata, M ; Nakajima, N ; Hamaji, M ; Sonobe, M ; Menju, T ; Date, H ; Haga, H</creator><creatorcontrib>Terada, K ; Yoshizawa, A ; Sumiyoshi, S ; Rokutan‐Kurata, M ; Nakajima, N ; Hamaji, M ; Sonobe, M ; Menju, T ; Date, H ; Haga, H</creatorcontrib><description><![CDATA[Cytokeratin 5 (CK5) is a marker for pulmonary squamous cell carcinoma; however, CK5 is sometimes present in pulmonary adenocarcinoma (ADC), and there is insufficient information regarding the clinicopathological features of CK5‐positive ADC. We aimed to explore the clinicopathological characteristics of CK5‐positive ADC using immunohistochemistry. We prepared the following two cohorts: a resected cohort containing 220 resected tumours for primarily studying the detailed morphological characteristics, and a tissue microarray (TMA) cohort containing 337 samples for investigating the associations of CK5 expression with other protein expressions, genetic and prognostic findings. CK5‐positive ADC was defined to have ≥ 10% tumour cells and presence of CK5‐positive tumour cells in the resected and TMA cohorts, respectively. CK5‐positive ADCs were identified in 91 (16.3%) patients in the combined cohort. CK5‐positive ADCs had male predominance (P = 0.012), smoking history (P = 0.001), higher stage (P < 0.001), histological high‐grade components (P < 0.001), vascular invasion (P < 0.001), mucinous differentiation (P < 0.001), spread through airspaces (P < 0.001), EGFR wild‐type (P < 0.001), KRAS mutations (P < 0.001), ALK rearrangement (P < 0.001) and ROS1 rearrangement (P = 0.002). In the resected cohort, more than half the CK5‐positive ADCs (19 cases, 65.5%) showed mucinous differentiation; the remaining cases harboured high‐grade components. In the TMA cohort, CK5‐positive ADCs correlated with TTF‐1 negativity (P = 0.002) and MUC5B, MUC5AC and HNF4alpha positivity (P < 0.001, 0.048, < 0.001). Further, CK5‐positive ADCs had significantly lower disease‐free and overall survival rates than CK5‐negative ADCs (P < 0.001 for each). Additionally, multivariate analysis revealed that CK5 expression was an independent poor prognostic factor. CK5‐positive ADCs showed aggressive clinical behaviour, with high‐grade morphology and mucinous differentiation.
XXX]]></description><identifier>ISSN: 0309-0167</identifier><identifier>EISSN: 1365-2559</identifier><identifier>DOI: 10.1111/his.14827</identifier><identifier>PMID: 36239561</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adenocarcinoma ; Adenocarcinoma - genetics ; Adenocarcinoma of Lung ; Biomarkers, Tumor - analysis ; Cancer ; Cytokeratin ; cytokeratin 5 ; Female ; high‐grade components ; Humans ; Immunohistochemistry ; Keratin-5 - analysis ; Lung carcinoma ; Lung Neoplasms - pathology ; Male ; mucinous differentiation ; Multivariate analysis ; Physical characteristics ; Prognosis ; Protein-Tyrosine Kinases ; Proto-Oncogene Proteins ; pulmonary adenocarcinoma ; Squamous cell carcinoma ; Tumors</subject><ispartof>Histopathology, 2023-02, Vol.82 (3), p.439-453</ispartof><rights>2022 John Wiley & Sons Ltd.</rights><rights>Copyright © 2023 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3537-993bc980efd70b2a51f3d44c7ee7420fdb855ed1e27cda0acb61ab1eba6324b53</citedby><cites>FETCH-LOGICAL-c3537-993bc980efd70b2a51f3d44c7ee7420fdb855ed1e27cda0acb61ab1eba6324b53</cites><orcidid>0000-0003-1462-7341</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36239561$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Terada, K</creatorcontrib><creatorcontrib>Yoshizawa, A</creatorcontrib><creatorcontrib>Sumiyoshi, S</creatorcontrib><creatorcontrib>Rokutan‐Kurata, M</creatorcontrib><creatorcontrib>Nakajima, N</creatorcontrib><creatorcontrib>Hamaji, M</creatorcontrib><creatorcontrib>Sonobe, M</creatorcontrib><creatorcontrib>Menju, T</creatorcontrib><creatorcontrib>Date, H</creatorcontrib><creatorcontrib>Haga, H</creatorcontrib><title>Clinicopathological features of cytokeratin 5‐positive pulmonary adenocarcinoma</title><title>Histopathology</title><addtitle>Histopathology</addtitle><description><![CDATA[Cytokeratin 5 (CK5) is a marker for pulmonary squamous cell carcinoma; however, CK5 is sometimes present in pulmonary adenocarcinoma (ADC), and there is insufficient information regarding the clinicopathological features of CK5‐positive ADC. We aimed to explore the clinicopathological characteristics of CK5‐positive ADC using immunohistochemistry. We prepared the following two cohorts: a resected cohort containing 220 resected tumours for primarily studying the detailed morphological characteristics, and a tissue microarray (TMA) cohort containing 337 samples for investigating the associations of CK5 expression with other protein expressions, genetic and prognostic findings. CK5‐positive ADC was defined to have ≥ 10% tumour cells and presence of CK5‐positive tumour cells in the resected and TMA cohorts, respectively. CK5‐positive ADCs were identified in 91 (16.3%) patients in the combined cohort. CK5‐positive ADCs had male predominance (P = 0.012), smoking history (P = 0.001), higher stage (P < 0.001), histological high‐grade components (P < 0.001), vascular invasion (P < 0.001), mucinous differentiation (P < 0.001), spread through airspaces (P < 0.001), EGFR wild‐type (P < 0.001), KRAS mutations (P < 0.001), ALK rearrangement (P < 0.001) and ROS1 rearrangement (P = 0.002). In the resected cohort, more than half the CK5‐positive ADCs (19 cases, 65.5%) showed mucinous differentiation; the remaining cases harboured high‐grade components. In the TMA cohort, CK5‐positive ADCs correlated with TTF‐1 negativity (P = 0.002) and MUC5B, MUC5AC and HNF4alpha positivity (P < 0.001, 0.048, < 0.001). Further, CK5‐positive ADCs had significantly lower disease‐free and overall survival rates than CK5‐negative ADCs (P < 0.001 for each). Additionally, multivariate analysis revealed that CK5 expression was an independent poor prognostic factor. CK5‐positive ADCs showed aggressive clinical behaviour, with high‐grade morphology and mucinous differentiation.
XXX]]></description><subject>Adenocarcinoma</subject><subject>Adenocarcinoma - genetics</subject><subject>Adenocarcinoma of Lung</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Cancer</subject><subject>Cytokeratin</subject><subject>cytokeratin 5</subject><subject>Female</subject><subject>high‐grade components</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Keratin-5 - analysis</subject><subject>Lung carcinoma</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>mucinous differentiation</subject><subject>Multivariate analysis</subject><subject>Physical characteristics</subject><subject>Prognosis</subject><subject>Protein-Tyrosine Kinases</subject><subject>Proto-Oncogene Proteins</subject><subject>pulmonary adenocarcinoma</subject><subject>Squamous cell carcinoma</subject><subject>Tumors</subject><issn>0309-0167</issn><issn>1365-2559</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp10E9LwzAcxvEgipvTg29ACl700C1_mmY9ylA3GIio55Kmv7rMtqlJq-zmS_A1-kqMdnoQzCWXDw_JF6FjgsfEn8lKuzGJplTsoCFhMQ8p58kuGmKGkxCTWAzQgXNrjIlglO6jAYspS3hMhuh2VupaK9PIdmVK86iVLIMCZNtZcIEpArVpzRNY2eo64B9v741xutUvEDRdWZla2k0gc6iNklbp2lTyEO0VsnRwtL1H6OHq8n42D5c314vZxTJUjDMRJgnLVDLFUOQCZ1RyUrA8ipQAEBHFRZ5NOYecABUql1iqLCYyI5DJmNEo42yEzvrdxprnDlybVtopKEtZg-lcSgXlFNMpx56e_qFr09nav86rOPbGt_DqvFfKGucsFGljdeU_mBKcfnVOfef0u7O3J9vFLqsg_5U_YT2Y9OBVl7D5fymdL-76yU8fbYlK</recordid><startdate>202302</startdate><enddate>202302</enddate><creator>Terada, K</creator><creator>Yoshizawa, A</creator><creator>Sumiyoshi, S</creator><creator>Rokutan‐Kurata, M</creator><creator>Nakajima, N</creator><creator>Hamaji, M</creator><creator>Sonobe, M</creator><creator>Menju, T</creator><creator>Date, H</creator><creator>Haga, H</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1462-7341</orcidid></search><sort><creationdate>202302</creationdate><title>Clinicopathological features of cytokeratin 5‐positive pulmonary adenocarcinoma</title><author>Terada, K ; Yoshizawa, A ; Sumiyoshi, S ; Rokutan‐Kurata, M ; Nakajima, N ; Hamaji, M ; Sonobe, M ; Menju, T ; Date, H ; Haga, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3537-993bc980efd70b2a51f3d44c7ee7420fdb855ed1e27cda0acb61ab1eba6324b53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adenocarcinoma</topic><topic>Adenocarcinoma - genetics</topic><topic>Adenocarcinoma of Lung</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Cancer</topic><topic>Cytokeratin</topic><topic>cytokeratin 5</topic><topic>Female</topic><topic>high‐grade components</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Keratin-5 - analysis</topic><topic>Lung carcinoma</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>mucinous differentiation</topic><topic>Multivariate analysis</topic><topic>Physical characteristics</topic><topic>Prognosis</topic><topic>Protein-Tyrosine Kinases</topic><topic>Proto-Oncogene Proteins</topic><topic>pulmonary adenocarcinoma</topic><topic>Squamous cell carcinoma</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Terada, K</creatorcontrib><creatorcontrib>Yoshizawa, A</creatorcontrib><creatorcontrib>Sumiyoshi, S</creatorcontrib><creatorcontrib>Rokutan‐Kurata, M</creatorcontrib><creatorcontrib>Nakajima, N</creatorcontrib><creatorcontrib>Hamaji, M</creatorcontrib><creatorcontrib>Sonobe, M</creatorcontrib><creatorcontrib>Menju, T</creatorcontrib><creatorcontrib>Date, H</creatorcontrib><creatorcontrib>Haga, H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Histopathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Terada, K</au><au>Yoshizawa, A</au><au>Sumiyoshi, S</au><au>Rokutan‐Kurata, M</au><au>Nakajima, N</au><au>Hamaji, M</au><au>Sonobe, M</au><au>Menju, T</au><au>Date, H</au><au>Haga, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinicopathological features of cytokeratin 5‐positive pulmonary adenocarcinoma</atitle><jtitle>Histopathology</jtitle><addtitle>Histopathology</addtitle><date>2023-02</date><risdate>2023</risdate><volume>82</volume><issue>3</issue><spage>439</spage><epage>453</epage><pages>439-453</pages><issn>0309-0167</issn><eissn>1365-2559</eissn><abstract><![CDATA[Cytokeratin 5 (CK5) is a marker for pulmonary squamous cell carcinoma; however, CK5 is sometimes present in pulmonary adenocarcinoma (ADC), and there is insufficient information regarding the clinicopathological features of CK5‐positive ADC. We aimed to explore the clinicopathological characteristics of CK5‐positive ADC using immunohistochemistry. We prepared the following two cohorts: a resected cohort containing 220 resected tumours for primarily studying the detailed morphological characteristics, and a tissue microarray (TMA) cohort containing 337 samples for investigating the associations of CK5 expression with other protein expressions, genetic and prognostic findings. CK5‐positive ADC was defined to have ≥ 10% tumour cells and presence of CK5‐positive tumour cells in the resected and TMA cohorts, respectively. CK5‐positive ADCs were identified in 91 (16.3%) patients in the combined cohort. CK5‐positive ADCs had male predominance (P = 0.012), smoking history (P = 0.001), higher stage (P < 0.001), histological high‐grade components (P < 0.001), vascular invasion (P < 0.001), mucinous differentiation (P < 0.001), spread through airspaces (P < 0.001), EGFR wild‐type (P < 0.001), KRAS mutations (P < 0.001), ALK rearrangement (P < 0.001) and ROS1 rearrangement (P = 0.002). In the resected cohort, more than half the CK5‐positive ADCs (19 cases, 65.5%) showed mucinous differentiation; the remaining cases harboured high‐grade components. In the TMA cohort, CK5‐positive ADCs correlated with TTF‐1 negativity (P = 0.002) and MUC5B, MUC5AC and HNF4alpha positivity (P < 0.001, 0.048, < 0.001). Further, CK5‐positive ADCs had significantly lower disease‐free and overall survival rates than CK5‐negative ADCs (P < 0.001 for each). Additionally, multivariate analysis revealed that CK5 expression was an independent poor prognostic factor. CK5‐positive ADCs showed aggressive clinical behaviour, with high‐grade morphology and mucinous differentiation.
XXX]]></abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36239561</pmid><doi>10.1111/his.14827</doi><tpages>453</tpages><orcidid>https://orcid.org/0000-0003-1462-7341</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0309-0167 |
| ispartof | Histopathology, 2023-02, Vol.82 (3), p.439-453 |
| issn | 0309-0167 1365-2559 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2725202850 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adenocarcinoma Adenocarcinoma - genetics Adenocarcinoma of Lung Biomarkers, Tumor - analysis Cancer Cytokeratin cytokeratin 5 Female high‐grade components Humans Immunohistochemistry Keratin-5 - analysis Lung carcinoma Lung Neoplasms - pathology Male mucinous differentiation Multivariate analysis Physical characteristics Prognosis Protein-Tyrosine Kinases Proto-Oncogene Proteins pulmonary adenocarcinoma Squamous cell carcinoma Tumors |
| title | Clinicopathological features of cytokeratin 5‐positive pulmonary adenocarcinoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T17%3A41%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinicopathological%20features%20of%20cytokeratin%205%E2%80%90positive%20pulmonary%20adenocarcinoma&rft.jtitle=Histopathology&rft.au=Terada,%20K&rft.date=2023-02&rft.volume=82&rft.issue=3&rft.spage=439&rft.epage=453&rft.pages=439-453&rft.issn=0309-0167&rft.eissn=1365-2559&rft_id=info:doi/10.1111/his.14827&rft_dat=%3Cproquest_cross%3E2725202850%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3537-993bc980efd70b2a51f3d44c7ee7420fdb855ed1e27cda0acb61ab1eba6324b53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2766285561&rft_id=info:pmid/36239561&rfr_iscdi=true |